Keywords: Alzheimer's disease, Market forecasts, USA, Eisai, Pfizer, Aricept, Novartis, Exelon, Forest, Namenda, Decision Resources

Insights on the US Alzheimer's disease market

Article | 03 December 2012

Print This

The treatment of Alzheimer's disease (AD) offers a compelling commercial opportunity for the pharmaceutical industry because of the large and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in